## Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

- 1: Authorisation Number
- 2: Name of authorisation holder
- 3: Address(es) of manufacturing site(s)

UK MIA(IMP) 59573 CGTC MANUFACTURING INNOVATION CENTRE LIMITED

CELL AND GENE THERAPY CATAPULT MANUFACTURING AND INNOVATION CENTRE, 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM

- 4: Legally registered address of authorisation holder
- 5: Scope of authorisation and dosage forms
- 6: Legal Basis of authorisation

7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation

8: Authorisation Date

9: Annexes attached

CGTC MANUFACTURING INNOVATION CENTRE LIMITED, 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM

ANNEX 1 and/ or ANNEX 2

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031]

Confidential

14/04/2025 Annex 1 and/or Annex 2

## SCOPE OF AUTHORISATION

Annex 2 Name and address of the site:

CELL AND GENE THERAPY CATAPULT MANUFACTURING AND INNOVATION CENTRE, 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM

Human Investigational Medicinal Products	
Authorised Operations	
MANUFACTURING OPERATIONS (according to part 1)	1
Part 1 - MANUFACTURING OPERATIONS [ 1.1 ] Sterile Investigational Medicinal Products [ 1.1.1 ] Aseptically prepared (processing operations for the following dosage forms) [ 1.1.1.1 ] Large volume liquids Special Requirements Live Cells Advanced Therapy Medicinal Products	NHR

[ 1.1.1.4 ] Small volume liquids	
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.1.1.6 ] Other aseptically prepared products	
Cell and viral vector based Advanced Therapeutic Medi	cinal Products
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.1.3 ] Batch certification	
[ 1.3 ] Biological investigational medicinal products	
[ 1.3.1 ] Biological medicinal products	
[ 1.3.1.3 ] Cell therapy products	
Special Requirements	7
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.3.1.4 ] Gene therapy products	
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	
[1.3.1.5] Biotechnology products	
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.3.1.6 ] Human or animal extracted products	
Special Requirements Live Cells	
Advanced Therapy Medicinal Products	
[ 1.3.1.8 ] Other biological medicinal products	
Viral vectors	
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.3.2 ] Batch certification	
[ 1.3.2.3 ] Cell therapy products	
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.3.2.4 ] Gene therapy products	
Special Requirements	•
Live Cells	
Advanced Therapy Medicinal Products	
[ 1.3.2.5 ] Biotechnology products	
Special Requirements	
Live Cells	
Advanced Therapy Medicinal Products	

[ 1.3.2.6 ] Human or animal extracted products
Special Requirements
Live Cells
Advanced Therapy Medicinal Products
[ 1.3.2.8 ] Other biological medicinal products
Viral vectors
Special Requirements
Live Cells
Advanced Therapy Medicinal Products
[ 1.4 ] Other investigational medicinal products or manufacturing activitiy
[ 1.4.2 ] Sterilisation of active substances/excipients/finished products:
[ 1.4.2.1 ] Filtration
[ 1.5 ] Packaging
[ 1.5.1 ] Primary packaging
[ 1.5.1.6 ] Liquids for internal use
[ 1.5.1.15 ] Other non-sterile medicinal products
Cell based Advanced Therapeutic Medicinal Products
[ 1.5.2 ] Secondary packaging
[ 1.6 ] Quality control testing
[ 1.6.1 ] Microbiological: sterility
[ 1.6.2 ] Microbiological: non-sterility
[ 1.6.3 ] Chemical/Physical

[ 1.6.4 ] Biological

MHRA-GMDP MHRA